Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis

Abstract

Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.

Different Anti-Vascular Endothelial Growth Factor for Patients With Diabetic Macular Edema: A Network Meta-Analysis

“…Our findings are consistent with the previous NMA that was published in 2018, reporting significant beneficial effects for patients receiving IVT-AFL compared with IVR 1 year after treatment ( Virgili et al, 2018 ). Unlike the 2018 review, here we focused on the three major types of anti-VEGF therapies that have been approved in China and included indirect evidence between anti-VEGF and steroids (such as dexamethasone implant) to supplement the analysis.…”

“…This review confirms the findings from a previous review ( Virgili et al, 2018 ) that IVT-AFL confers benefits over IVR at 1 year. Our review included studies with a broad range of characteristics in DME patients and included the latest evidence of IVC in NMA.…”

Different Anti-Vascular Endothelial Growth Factor for Patients With Diabetic Macular Edema: A Network Meta-Analysis

“…Our findings are consistent with the previous NMA that was published in 2018, reporting significant beneficial effects for patients receiving IVT-AFL compared with IVR 1 year after treatment ( Virgili et al, 2018 ). Unlike the 2018 review, here we focused on the three major types of anti-VEGF therapies that have been approved in China and included indirect evidence between anti-VEGF and steroids (such as dexamethasone implant) to supplement the analysis.…”

“…This review confirms the findings from a previous review ( Virgili et al, 2018 ) that IVT-AFL confers benefits over IVR at 1 year. Our review included studies with a broad range of characteristics in DME patients and included the latest evidence of IVC in NMA.…”

<p>Two Year Visual Acuity and Structural Outcomes in Patients with Diabetic Macular Oedema Treated with Intravitreal Aflibercept – A Retrospective Cohort Study</p>

“……”

Ranibizumab or Aflibercept for Diabetic Macular Edema

“…A Cochrane meta-analysis identified a visual advantage of aflibercept over ranibizumab 0.3mg one year after starting treatment. 7 Here we have found that aflibercept also appears to be more effective than 0.5 mg ranibizumab in improving vision at one year in eyes with VA ≤ 68 letters at the start of treatment, as was reported by The DRCR.net Protocol T for 0.3mg ranibizumab. 5 The visual gains in both the treatment groups were similar in eyes with initial VA≥ 69 letters, perhaps due to the ceiling effect when treating patients with good vision at baseline.…”

Different Anti-Vascular Endothelial Growth Factor for Patients With Diabetic Macular Edema: A Network Meta-Analysis

“…Our findings are consistent with the previous NMA that was published in 2018, reporting significant beneficial effects for patients receiving IVT-AFL compared with IVR 1 year after treatment ( Virgili et al, 2018 ). Unlike the 2018 review, here we focused on the three major types of anti-VEGF therapies that have been approved in China and included indirect evidence between anti-VEGF and steroids (such as dexamethasone implant) to supplement the analysis.…”

“…This review confirms the findings from a previous review ( Virgili et al, 2018 ) that IVT-AFL confers benefits over IVR at 1 year. Our review included studies with a broad range of characteristics in DME patients and included the latest evidence of IVC in NMA.…”

<p>Two Year Visual Acuity and Structural Outcomes in Patients with Diabetic Macular Oedema Treated with Intravitreal Aflibercept – A Retrospective Cohort Study</p>

“……”

Ranibizumab or Aflibercept for Diabetic Macular Edema

“…A Cochrane meta-analysis identified a visual advantage of aflibercept over ranibizumab 0.3mg one year after starting treatment. 7 Here we have found that aflibercept also appears to be more effective than 0.5 mg ranibizumab in improving vision at one year in eyes with VA ≤ 68 letters at the start of treatment, as was reported by The DRCR.net Protocol T for 0.3mg ranibizumab. 5 The visual gains in both the treatment groups were similar in eyes with initial VA≥ 69 letters, perhaps due to the ceiling effect when treating patients with good vision at baseline.…”

Different Anti-Vascular Endothelial Growth Factor for Patients With Diabetic Macular Edema: A Network Meta-Analysis

“…Our findings are consistent with the previous NMA that was published in 2018, reporting significant beneficial effects for patients receiving IVT-AFL compared with IVR 1 year after treatment ( Virgili et al, 2018 ). Unlike the 2018 review, here we focused on the three major types of anti-VEGF therapies that have been approved in China and included indirect evidence between anti-VEGF and steroids (such as dexamethasone implant) to supplement the analysis.…”

“…This review confirms the findings from a previous review ( Virgili et al, 2018 ) that IVT-AFL confers benefits over IVR at 1 year. Our review included studies with a broad range of characteristics in DME patients and included the latest evidence of IVC in NMA.…”

<p>Two Year Visual Acuity and Structural Outcomes in Patients with Diabetic Macular Oedema Treated with Intravitreal Aflibercept – A Retrospective Cohort Study</p>

“……”

Ranibizumab or Aflibercept for Diabetic Macular Edema

“…A Cochrane meta-analysis identified a visual advantage of aflibercept over ranibizumab 0.3mg one year after starting treatment. 7 Here we have found that aflibercept also appears to be more effective than 0.5 mg ranibizumab in improving vision at one year in eyes with VA ≤ 68 letters at the start of treatment, as was reported by The DRCR.net Protocol T for 0.3mg ranibizumab. 5 The visual gains in both the treatment groups were similar in eyes with initial VA≥ 69 letters, perhaps due to the ceiling effect when treating patients with good vision at baseline.…”